About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

News

February 13, 2019
Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

February 5, 2019
Caladrius Biosciences to Present at Upcoming February Conferences

January 7, 2019
Caladrius Biosciences to Participate in Upcoming January Conferences

Events

February 12, 2019
Caladrius Biosciences to Present at the 2019 BIO CEO Investor Conference

November 8, 2018
Third Quarter 2018 Financial Results Call

October 4, 2018
2018 Cell and Gene Meeting on the Mesa – Partnering Forum

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology